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high-technology simulators before moving on 
to real-life scenarios and live firing missions, 
with a similar acquisition of skills as used to 
train novice surgeons.
However, questions remain unanswered: 
When, for how long and what types of video 
games are best? If skills are best developed 
when younger, then would video gaming 
practice during surgical training be fruitless? 
Should we be advising more Chinese take-
aways to enhance chopstick skills while doing 
surgical on-calls? More concerning are the 
studies showing that young people who 
played violent games tended to be more 
aggressive, less forgiving and believed 
violence to be normal, compared to those who 
played non-violent games. Also, those who 
played more entertainment games did less 
well in school and were at greater risk of 
obesity.
Does the evidence support a role for video 
gaming in laparoscopic training? There 
appears to be a positive relationship and it is 
tempting to encourage video gaming in 
laparoscopic departments as a relatively 
cheap, enjoyable and readily available adjunct 
to laparoscopic training. However, we need to 
avoid training methods that lead to violence, 
obesity and other, as yet undetermined, 
consequences. Ideally, the combined opinion 
of psychologists, medical educationalists and 
laparoscopists, alongside further larger 
studies, is needed before video gaming could 
be accepted as good practice, and before we 
can relax general concerns about video 
gaming amongst the younger generation.
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INTRODUCTION
 
The coincidence of prostate and bladder 
cancer occurring together in the same 
individual is considered common. One factor 
to be considered is the likelihood of diagnostic 
bias when the presence of one genitourinary 
cancer leads to a more detailed clinical and 
pathological examination, resulting in the 
incidental diagnosis of another genitourinary 
cancer. Singh 
 
et al.
 
 [1] evaluated the risk of 
prostate cancer as a second malignancy in 
patients diagnosed with bladder cancer 
after adjusting for possible diagnostic and 
treatment biases. The standardized incidence 
ratio (actual number of cases in a population 
at a given time to the number that would be 
expected based on the cancer rates in the 
same area) of prostate cancer in patients with 
urothelial cancer was significantly increased. 
The same ratio was not increased for other 
malignancies.
The high coincidence of prostate and bladder 
cancers occurring together might be also 
explained by a common carcinogenic pathway. 
Tumour-suppressor genes might be crucial in 
the development of both [2]. Amara 
 
et al.
 
 [3] 
showed by immunohistochemical analysis 
that prostate stem-cell antigen is over-
expressed in most TCCs. Despite these findings, 
the model for a common carcinogenic 
pathway remains to be confirmed.
 
ADENOCARCINOMA OF THE PROSTATE: 
ITS BURDEN IN CYSTOPROSTATECTOMY 
SPECIMENS
 
As recently addressed by Saad 
 
et al.
 
 [4], 
cystoprostatectomy specimens provide a 
unique chance to define the features of silent 
adenocarcinoma of the prostate. The 
variability of its frequency can be explained in 
the first instance by the sampling approach 
adopted to process the prostate. When slices 
are too thick, small foci of cancer might 
remain undetected because they remain 
‘buried’. The advantage of complete sampling 
over partial sampling is that small foci of 
cancer are seen more frequently and cancer 
features, such extraprostatic extension and 
positive margins, are more accurately 
evaluated. Using the technique of McNeal 
 
et al.
 
 [5], with slices taken every 2.5 mm from 
the base to the apex of the gland, a high 
incidence of prostate cancer can found. 
Ruffion 
 
et al.
 
 [6] detected an incidental 
prostate cancer in 51% of their samples. 
Similar results were obtained by others with 
serial step-sections taken at 2–3 mm intervals 
[7,8]. Winkler 
 
et al.
 
 [9] reported the highest 
detection rate so far (60%) by using 2 mm 
sections. Nevertheless, although using the 
same technique, Cindolo 
 
et al.
 
 [10] reported 
much lower rates (12.6%), as also did Saad 
 
et al.
 
 [4]. However, there is a similar wide 
variability when using a pathological protocol 
 C O M M E N T S
 
©
 
 
 
2 0 0 9  T H E  A U T H O R S
J O U R N A L  C O M P I L A T I O N  
 
©
 
 2 0 0 9  B J U  I N T E R N A T I O N A L
 
1 6 1
 
with 5-mm sections. The detection rate 
increased to 42% in the study by Montironi 
 
et al.
 
 [8], whereas it was surprisingly low (4%) 
in a recent report from a Taiwanese group [11]. 
This latter result might be influenced by the 
lower incidence of prostate cancer in Asian 
countries. Some studies do not include a 
description of the applied histopathological 
evaluation [12].
 
CLINICAL SIGNIFICANCE OF AN 
INCIDENTALLY DISCOVERED 
PROSTATE CANCER
 
Stamey 
 
et al.
 
 [13] discovered unsuspected 
prostate cancer in 40% of a group of 
cystoprostatectomy specimens. Reasoning 
that according to epidemiological data only 
8% of prostate cancers are clinically apparent, 
and that these must be the largest, they took 
8% of the largest tumours identified in their 
series (0.5–6.1 mL) and concluded that 
any tumour of 
 
>
 
0.5 mL must be clinically 
significant. With the additional inclusion of 
any poorly differentiated Gleason 4 or 5 
cancer, the 0.5 mL size criteria for a ‘clinically 
significant’ tumour has gained wide 
recognition.
Authors attempted to incorporate PSA levels 
into predictive models of tumour significance. 
However, Winkler 
 
et al.
 
 [9] found a weak 
correlation between PSA levels and tumour 
volume, and no difference between median 
PSA values for patients with and without 
prostate cancer.
Revelo 
 
et al.
 
 [7] reported a 41% rate of 
unsuspected prostate adenocarcinoma, only 
48% of these being considered clinically 
significant. The presence of clinically 
significant prostate cancer in the study by 
Barbisan 
 
et al.
 
 [14] was much higher (81%) 
than previously reported.
A few non-morphological studies have 
indicated that incidental cancer is different 
from clinical cancer in terms of marker 
expression. In particular, it has cell features of 
less aggressiveness than clinically detected 
cancers [15].
 
PATIENTS WITH CONCOMITANT PROSTATE 
AND BLADDER CANCER, AND THEIR FATE
 
Androulakakis 
 
et al.
 
 [16] initially suggested 
that the prognosis in these patients appears 
to be related to the characteristics of each 
tumour, separately. Konski 
 
et al.
 
 [17] reported 
that most of the patients presented with 
an early stage of one malignancy and an 
advanced stage of the other. In their 
experience, patients presenting with prostate 
cancer had a better 5-year survival rate (50%) 
than those presenting with bladder cancer 
(32%). The most significant prognostic factor 
was the stage of the bladder cancer.
More recently, Delongchamps 
 
et al.
 
 [18] 
reported on 141 patients with invasive bladder 
cancer, mostly of an advanced tumour stage; 
20 (14%) had incidental prostate cancer. 
Ten patients died from bladder cancer after 
a median interval of 13 months. The poor 
survival rate was due to the advanced stage of 
the bladder tumours seen in the most patients.
Despite a limited amount and profile of 
available data, it can be concluded that the 
outcome of patients with incidentally 
discovered prostate cancer after 
cystoprostatectomy depends on the 
prognosis of the bladder tumour.
 
HOW DOES PSA WORK IN THESE CASES?
 
Winkler 
 
et al.
 
 [9] found a statistically 
significantly higher PSA level in those with 
incidental prostate cancer, but in the study by 
Ruffion 
 
et al.
 
 [6] the mean PSA level in the 
prostate cancer group was 2.84 ng/mL, which 
was similar to that in the group without 
prostate cancer (2.19 ng/mL). The authors 
could not find a plasma PSA threshold 
beneath which there was a 
 
<
 
5% association 
with prostate cancer. More recently, Rocco 
 
et al.
 
 [19] concluded that PSA levels in their 
series did not correlate either with the overall 
risk of prostate cancer or with the risk of 
clinically significant disease. Saad 
 
et al.
 
 [4] 
found no significant correlation between 
preoperative PSA levels and the presence 
of adenocarcinoma, the Gleason score or 
prostatic tumour stage.
Based on the available data, for those who are 
candidates for prostate-sparing surgery, it 
seems reasonable to include a routine 
prostate biopsy in the standard preoperative 
evaluation, even in men with a normal DRE 
and PSA levels.
 
UROTHELIAL PROSTATE CANCER: 
ITS INCIDENCE AND PROGNOSTIC 
SIGNIFICANCE
 
Reports of prostatic urethral involvement at 
the time of radical cystectomy are mostly 
retrospective and lack careful pathological 
assessment of the prostate. Thus, it is likely 
that the true incidence of involvement with 
urothelial carcinoma is under-reported. 
However, the incidence of prostatic urethral 
involvement approaches 50% in series in 
which there is a detailed pathological 
assessment of the prostate [20].
In a prospective pathological assessment 
of 121 consecutive cystoprostatectomy 
specimens analysed by whole mounts, Revelo 
 
et al.
 
 [7] found urothelial carcinoma involving 
the prostatic urethra in 48% of cases, 33% of 
them having apical involvement. All prostates 
with prostatic apical involvement through 
urothelial carcinoma uniformly had 
involvement of more proximal portions of the 
prostate. These results support the concept of 
standard cystoprostatectomy.
Retrospective studies have suggested that 
multifocal bladder tumours, carcinoma 
 
in 
situ
 
 (CIS) in the bladder and bladder tumour 
location in the bladder neck are independent 
risk factors for prostatic urothelial 
carcinoma in men undergoing radical 
cystectomy [20].
Interestingly, Pettus 
 
et al.
 
 [21] found that 
bladder tumours at or below the trigone and 
CIS in the bladder were associated with 
prostatic involvement. However, the absence 
of one or both of these factors was not 
adequate to identify the entire population 
of patients without prostatic urothelial 
tumour.
In this respect, limited biopsies of the prostate 
urothelium are not adequate to identify 
prostatic urothelial cancer. Donat 
 
et al.
 
 [22] 
took a transurethral biopsy of the prostatic 
urethra in 246 men undergoing radical 
cystectomy. The sensitivity of transurethral 
biopsy for prostatic stromal invasion was 53% 
and the specificity was 77%, for a positive 
predictive value of 45% and a negative 
predictive value of 82%.
Prostatic involvement in urothelial bladder 
cancer is considered to be an advanced 
disease. The TNM classification categorises 
prostate involvement as stage pT4a. This 
classification does not differentiate 
contiguous (transmural invasion of the 
bladder tumour) and non-contiguous (tumour 
arising in the prostatic urethra) involvement, 
which are distinct clinicopathological entities 
with a dissimilar prognosis.
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In the report by Ayyathurai 
 
et al.
 
 [23] there 
was no statistically significant survival 
difference between those with contiguous 
and non-contiguous stromal involvement. 
This emphasizes that the depth of invasion 
in the prostate, rather than the mode of 
invasion, affects the outcome. Prostatic 
stromal involvement, which reflects the depth 
of invasion, is the most important prognostic 
factor and the international consensus 
committee on bladder cancer concluded that 
the TNM classification of urothelial bladder 
cancer defines pT4a as prostatic stromal 
invasion [24].
 
CONCLUSIONS
 
Incidental prostate adenocarcinoma has a 
variable incidence in cystectomy specimens. 
Its clinical significance remains questionable, 
as the outcome of patients depends on the 
prognosis of the bladder tumour. For those 
candidates for prostate-sparing surgery, it 
seems reasonable to include a routine 
prostate biopsy in the standard preoperative 
evaluation. Even if it is likely that its true 
incidence is under-reported, urothelial 
involvement of the prostate in 
cystoprostatectomy specimens is common. 
Multifocal bladder tumours, CIS in the 
bladder and bladder tumour in the bladder 
neck are independent risk factors for 
prostatic urothelial carcinoma. The most 
important finding in predicting prognosis is 
the depth of invasion, as reflected by stromal 
involvement, and not the route of invasion.
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